Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study
British Journal of Haematology · 2026-08 · 209 (2) · 534-543
DOI: 10.1111/bjh.70634 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift British Journal of Haematology, online erschienen am 23.06.2026. Verfasst von Yoann Zelmat und 5 weiteren Autor:innen. Beteiligte Einrichtung: Université de Toulouse, CHU de Toulouse, Service de Pharmacologie, Toulouse, France. Hauptthemen laut MEDLINE: Atrial Fibrillation, Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bruton's tyrosine kinase inhibitors (BTKi) are widely used in B‐cell malignancies. Ibrutinib is associated with atrial fibrillation (AF), but comparative real‐world evidence on AF risk across BTKi remains limited. We conducted a nationwide new‐user population study using the French national health insurance database (2015–2024). Adults initiating ibrutinib, acalabrutinib, zanubrutinib or venetoclax were included, excluding those with prior AF or non‐overlapping BTKi indications. The primary outcome was AF requiring hospitalization. Hazard ratios (HRs) were estimated using Cox models with inverse probability of treatment weighting (IPTW). Among 26 393 patients, median follow‐up ranged from 167 days in the zanubrutinib cohort to 526 days in the ibrutinib cohort. One‐year incidence of hospitalized AF was highest with ibrutinib (2.3%) versus acalabrutinib (0.9%), zanubrutinib (0.7%) and venetoclax (0.5%). Ibrutinib was associated with a significantly higher AF risk versus acalabrutinib (HR 3.03, 95% confidence interval [CI] 1.84–5.00), zanubrutinib (HR 7.58, 95% CI 2.05–28.06) and venetoclax (HR 9.04, 95% CI 5.81–14.04). No significant differences in AF risk were observed between second‐generation BTKi and venetoclax. Ibrutinib was associated with a substantially higher risk of hospitalized AF than second‐generation BTKi, supporting closer cardiac monitoring in ibrutinib‐treated patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université de Toulouse, CHU de Toulouse, Service de Pharmacologie, Toulouse, France.
- Institut des Maladies Cardiovasculaires et métabolique (I2MC), UMR 1297, Université de Toulouse, INSERM, Toulouse, France.
- Université de Toulouse, CHU de Toulouse, Institut Universitaire du Cancer de Toulouse - Oncopôle, Service d'hématologie, Toulouse, France.
- Centre de Recherche Contre le Cancer (CRCT), UMR1037, INSERM, Toulouse, France.
- Université de Toulouse, CHU de Toulouse, Service de Cardiologie, Toulouse, France.
- Centre d'investigation Clinique CIC1436, CHU de Toulouse, Université de Toulouse, INSERM, Toulouse, France.
ORCID-Profile: Yoann Zelmat, Loic Ysebaert, Paul Gautier, Agnes Sommet, Margaux Lafaurie, Fabien Despas
Zitieren
APA
Zelmat, Y., Ysebaert, L., Gautier, P., Sommet, A., Lafaurie, M., & Despas, F. (2026). Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study. British Journal of Haematology, 209(2), 534-543. https://doi.org/10.1111/bjh.70634
Vancouver
Zelmat Y, Ysebaert L, Gautier P, Sommet A, Lafaurie M, Despas F. Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study. British Journal of Haematology. 2026;209(2):534-543. doi:10.1111/bjh.70634
BibTeX
@article{Zelmat2026,
author = {Zelmat, Yoann and Ysebaert, Loic and Gautier, Paul and Sommet, Agnes and Lafaurie, Margaux and Despas, Fabien},
title = {Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A nationwide population‐based study},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {2},
pages = {534--543},
doi = {10.1111/bjh.70634}
}
EUVIMED